Fig 1: TIAL1 is a direct target of miR-223-3p in HN-H cells. (A) Bioinformatics analysis predicted the 3'-UTR of TIAL1 to be a putative seed sequence of miR-223-3p. (B) Western blot analysis indicated that DEX inhibited H2O2-induced TIAL1 expression. **P<0.01, ****P<0.0001 vs. control untreated cells (DEX=0 µM, H2O2=0 µM); #P<0.05 vs. the 200 µM H2O2 treatment group. (C) miR-223-3p overexpression inhibits TIAL1 expression. ****P<0.0001 vs. control mimic; #P<0.05 vs. control inhibitor group. (D) Luciferase assay indicated that TIAL1 is a direct target of mir-223-3p. ****P<0.0001 vs. control mimic; #P<0.05 vs. control inhibitor group. (E) Transfection efficiency assessment. ****P<0.0001 vs. control vector. (F) Overexpression of TIAL1 abrogated the effect of DEX on cell viability. *P<0.05, ****P<0.0001 vs. control cells (DEX=0 µM, H2O2=200 µM, pcDNA vector); #P<0.05 vs. the TIAL1 vector group (DEX=0 µM, H2O2=200 µM, pcDNA+TIAL1 vector). The experiments were performed three times in duplicate. DEX, dexmedetomidine; TIAL1, TIA1 cytotoxic granule associated RNA binding protein like 1; miR, microRNA; UTR, untranslated region; NS, not significant; miR, microRNA.
Supplier Page from Abcam for Anti-TIAL1 antibody